Michael Gerard - 18 Jan 2023 Form 4 Insider Report for Cabaletta Bio, Inc. (CABA)

Reporting relationship: General Counsel
Issuer ticker: CABA
Reported as of: 18 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Jan 2023, 19:52:02 UTC
Prior SEC filing: 19 Jan 2022
Next SEC filing: 04 Mar 2024
Source filing: View source filing
Reporting owner signature: By: /s/ Michael Gerard

Key filing fact

Michael Gerard filed Form 4 for Cabaletta Bio, Inc. (CABA) on 27 Jan 2023.

Key facts

This page summarizes Michael Gerard's Form 4 filing for Cabaletta Bio, Inc. (CABA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 Jan 2023, 19:52.

Change

Previous filing in this sequence was filed on 19 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CABA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +112,500
Change %
Price: $0.000000
Shares after: 112,500
Date: 18 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 112,500
Exercise price: $11.09
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares underlying this option shall vest and become exercisable on January 18, 2024, with the remainder vesting in twelve substantially equal quarterly installments thereafter, subject to the reporting person's continued service on each such vesting date.